Merck & Co. Statistics
Total Valuation
Merck & Co. has a market cap or net worth of $209.32 billion. The enterprise value is $234.94 billion.
| Market Cap | 209.32B |
| Enterprise Value | 234.94B |
Important Dates
The next confirmed earnings date is Tuesday, July 29, 2025, before market open.
| Earnings Date | Jul 29, 2025 |
| Ex-Dividend Date | Jun 16, 2025 |
Share Statistics
Merck & Co. has 2.51 billion shares outstanding. The number of shares has decreased by -0.30% in one year.
| Current Share Class | 2.51B |
| Shares Outstanding | 2.51B |
| Shares Change (YoY) | -0.30% |
| Shares Change (QoQ) | -0.24% |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 80.63% |
| Float | 2.51B |
Valuation Ratios
The trailing PE ratio is 12.12 and the forward PE ratio is 9.33. Merck & Co.'s PEG ratio is 1.11.
| PE Ratio | 12.12 |
| Forward PE | 9.33 |
| PS Ratio | 3.30 |
| Forward PS | 3.17 |
| PB Ratio | 4.34 |
| P/TBV Ratio | 19.22 |
| P/FCF Ratio | 12.28 |
| P/OCF Ratio | 10.03 |
| PEG Ratio | 1.11 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.16, with an EV/FCF ratio of 13.79.
| EV / Earnings | 13.48 |
| EV / Sales | 3.68 |
| EV / EBITDA | 8.16 |
| EV / EBIT | 9.62 |
| EV / FCF | 13.79 |
Financial Position
The company has a current ratio of 1.41, with a Debt / Equity ratio of 0.72.
| Current Ratio | 1.41 |
| Quick Ratio | 0.83 |
| Debt / Equity | 0.72 |
| Debt / EBITDA | 1.20 |
| Debt / FCF | 2.04 |
| Interest Coverage | 19.06 |
Financial Efficiency
Return on equity (ROE) is 39.29% and return on invested capital (ROIC) is 19.33%.
| Return on Equity (ROE) | 39.29% |
| Return on Assets (ROA) | 13.81% |
| Return on Invested Capital (ROIC) | 19.33% |
| Return on Capital Employed (ROCE) | 27.14% |
| Revenue Per Employee | $852,293 |
| Profits Per Employee | $232,453 |
| Employee Count | 75,000 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 2.31 |
Taxes
In the past 12 months, Merck & Co. has paid $2.72 billion in taxes.
| Income Tax | 2.72B |
| Effective Tax Rate | 13.48% |
Stock Price Statistics
The stock price has decreased by -34.52% in the last 52 weeks. The beta is 0.40, so Merck & Co.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.40 |
| 52-Week Price Change | -34.52% |
| 50-Day Moving Average | 79.37 |
| 200-Day Moving Average | 92.36 |
| Relative Strength Index (RSI) | 60.87 |
| Average Volume (20 Days) | 18,210,778 |
Short Selling Information
The latest short interest is 35.80 million, so 1.43% of the outstanding shares have been sold short.
| Short Interest | 35.80M |
| Short Previous Month | 41.27M |
| Short % of Shares Out | 1.43% |
| Short % of Float | 1.43% |
| Short Ratio (days to cover) | 2.50 |
Income Statement
In the last 12 months, Merck & Co. had revenue of $63.92 billion and earned $17.43 billion in profits. Earnings per share was $6.88.
| Revenue | 63.92B |
| Gross Profit | 49.27B |
| Operating Income | 24.41B |
| Pretax Income | n/a |
| Net Income | 17.43B |
| EBITDA | 28.80B |
| EBIT | 24.41B |
| Earnings Per Share (EPS) | $6.88 |
Balance Sheet
The company has $9.23 billion in cash and $34.84 billion in debt, giving a net cash position of -$25.62 billion or -$10.20 per share.
| Cash & Cash Equivalents | 9.23B |
| Total Debt | 34.84B |
| Net Cash | -25.62B |
| Net Cash Per Share | -$10.20 |
| Equity (Book Value) | 48.40B |
| Book Value Per Share | 19.21 |
| Working Capital | 10.33B |
Cash Flow
In the last 12 months, operating cash flow was $20.88 billion and capital expenditures -$3.84 billion, giving a free cash flow of $17.04 billion.
| Operating Cash Flow | 20.88B |
| Capital Expenditures | -3.84B |
| Free Cash Flow | 17.04B |
| FCF Per Share | $6.79 |
Margins
Gross margin is 77.07%, with operating and profit margins of 38.19% and 27.27%.
| Gross Margin | 77.07% |
| Operating Margin | 38.19% |
| Pretax Margin | 31.55% |
| Profit Margin | 27.27% |
| EBITDA Margin | 45.05% |
| EBIT Margin | 38.19% |
| FCF Margin | 26.66% |
Dividends & Yields
This stock pays an annual dividend of $3.24, which amounts to a dividend yield of 3.89%.
| Dividend Per Share | $3.24 |
| Dividend Yield | 3.89% |
| Dividend Growth (YoY) | 5.26% |
| Years of Dividend Growth | 14 |
| Payout Ratio | 46.52% |
| Buyback Yield | 0.30% |
| Shareholder Yield | 4.15% |
| Earnings Yield | 8.33% |
| FCF Yield | 8.14% |
Analyst Forecast
The average price target for Merck & Co. is $113.14, which is 35.73% higher than the current price. The consensus rating is "Buy".
| Price Target | $113.14 |
| Price Target Difference | 35.73% |
| Analyst Consensus | Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (5Y) | 2.35% |
| EPS Growth Forecast (5Y) | 8.65% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on February 17, 1999. It was a forward split with a ratio of 2:1.
| Last Split Date | Feb 17, 1999 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Merck & Co. has an Altman Z-Score of 4.7 and a Piotroski F-Score of 7.
| Altman Z-Score | 4.7 |
| Piotroski F-Score | 7 |